Showing 1 - 4 results of 4 for search 'Nicole Grunenberg', query time: 0.01s Refine Results
  1. 1
    Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses

    Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses by Ying Huang, Shomoita Alam, Erica Andersen-Nissen, Lindsay N. Carpp, One B. Dintwe, Britta S. Flach, Nicole Grunenberg, Fatima Laher, Stephen C. De Rosa, Guido Ferrari, Craig Innes, Linda-Gail Bekker, James G. Kublin, M. Juliana McElrath, Georgia D. Tomaras, Glenda E. Gray, Peter B. Gilbert

    Published 2024-08-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.

    Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. by Erica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, Lindsay N Carpp, Anneta F Naidoo, Michael S Harper, Valentin Voillet, Nicole Grunenberg, Fatima Laher, Craig Innes, Linda-Gail Bekker, James G Kublin, Ying Huang, Guido Ferrari, Georgia D Tomaras, Glenda Gray, Peter B Gilbert, M Juliana McElrath

    Published 2021-03-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

    Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomize... by Vimla Naicker, Fatima Laher, Linda-Gail Bekker, Kelly E Seaton, Mary Allen, Stephen De Rosa, Nicole L Yates, Nonhlanhla N Mkhize, Kevin Saunders, Jack Heptinstall, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Chenchen Yu, Tandile Modise, Valerie Bekker, Nicole Grunenberg, Briana Furch, Maurine D Miner, Sanjay Phogat, Carlos A Diazgranados, Sanjay Gurunathan, Marguerite Koutsoukos, Olivier Van Der Meeren, Alison C Roxby, Guido Ferrari, Lynn Morris, David Montefiori, M Juliana McElrath, Georgia D Tomaras, Zoe Moodie

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

    A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13... by Zoe Moodie, Shuying Sue Li, Elena E. Giorgi, LaTonya D. Williams, One Dintwe, Lindsay N. Carpp, Shiyu Chen, Kelly E. Seaton, Sheetal S. Sawant, Lu Zhang, Jack Heptinstall, Shuying Liu, Nicole Grunenberg, Frank Tomaka, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Julie A. Ake, Sandhya Vasan, Giuseppe Pantaleo, Ian Frank, Lindsey R. Baden, Paul A. Goepfert, Michael Keefer, Mike Chirenje, Mina C. Hosseinipour, Kathryn Mngadi, Fatima Laher, Nigel Garrett, Linda-Gail Bekker, Stephen De Rosa, Erica Andersen-Nissen, James G. Kublin, Shan Lu, Peter B. Gilbert, Glenda E. Gray, Lawrence Corey, M. Juliana McElrath, Georgia D. Tomaras

    Published 2025-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: